Change in Age of Diagnosis and Demographics of Type 1 Diabetes Mellitus During the COVID-19 Era.

IF 1.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Pediatric Diabetes Pub Date : 2025-10-16 eCollection Date: 2025-01-01 DOI:10.1155/pedi/7276579
Katya Sracic, Naveen Uli, Ryan Heksch
{"title":"Change in Age of Diagnosis and Demographics of Type 1 Diabetes Mellitus During the COVID-19 Era.","authors":"Katya Sracic, Naveen Uli, Ryan Heksch","doi":"10.1155/pedi/7276579","DOIUrl":null,"url":null,"abstract":"<p><p>Since COVID-19 onset, pediatric endocrinologists have been making an assumption that there was a shift in diagnosis age of type 1 diabetes mellitus (T1DM) to younger children. Younger children are more likely to present in DKA, are more difficult to diagnose and treat, and age at diagnosis can affect prognosis. We performed a retrospective chart review of patients diagnosed with T1DM for 3 years before COVID-19 and the 3 years during COVID-19. Demographics were evaluated using the Chi-squared test for categorical data and Student's <i>t</i>-test or ANOVA for continuous data. During this time, 698 patients were diagnosed with T1DM, with more patients during COVID-19. The average age of diagnosis significantly increased by 0.7 years (<i>p</i>=0.025). There was a significant difference in the distribution of age groups between the two time periods (<i>p</i>=0.0065). There was a significant decrease in new cases among patients between the ages of 2-5 years from 2017 to 2020, a transient finding as they reverted back to previous rates by 2022. New diagnoses between 13 and 18 years were increasing prior to 2020 (7%-23%), subsequently leveling out. Patients were 1.6 times more likely to present in DKA during COVID-19; however, there was no significant change in hemoglobin A1c (HbA1c). There was no significant change in thyroperoxidase (TPO) antibody positivity. There was a significant decrease (<i>p</i>=0.018) in patients with elevated tissue transglutaminase (TTG)-IgA from pre-COVID to post-COVID. Average age at diagnosis in our cohort increased since the start of COVID-19, contradicting previous studies and our hypothesis. The number of new cases increased, and the age distribution changed. There was a significant decrease in number of younger patients in 2020, followed by a normalization of new cases in those 2-5 years old, which may have led to the belief that more toddlers were being diagnosed. The rate of other antibodies did not increase. These results illustrate that changes in demographics may have been short-lived post-COVID-19.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"7276579"},"PeriodicalIF":1.9000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12549198/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/pedi/7276579","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Since COVID-19 onset, pediatric endocrinologists have been making an assumption that there was a shift in diagnosis age of type 1 diabetes mellitus (T1DM) to younger children. Younger children are more likely to present in DKA, are more difficult to diagnose and treat, and age at diagnosis can affect prognosis. We performed a retrospective chart review of patients diagnosed with T1DM for 3 years before COVID-19 and the 3 years during COVID-19. Demographics were evaluated using the Chi-squared test for categorical data and Student's t-test or ANOVA for continuous data. During this time, 698 patients were diagnosed with T1DM, with more patients during COVID-19. The average age of diagnosis significantly increased by 0.7 years (p=0.025). There was a significant difference in the distribution of age groups between the two time periods (p=0.0065). There was a significant decrease in new cases among patients between the ages of 2-5 years from 2017 to 2020, a transient finding as they reverted back to previous rates by 2022. New diagnoses between 13 and 18 years were increasing prior to 2020 (7%-23%), subsequently leveling out. Patients were 1.6 times more likely to present in DKA during COVID-19; however, there was no significant change in hemoglobin A1c (HbA1c). There was no significant change in thyroperoxidase (TPO) antibody positivity. There was a significant decrease (p=0.018) in patients with elevated tissue transglutaminase (TTG)-IgA from pre-COVID to post-COVID. Average age at diagnosis in our cohort increased since the start of COVID-19, contradicting previous studies and our hypothesis. The number of new cases increased, and the age distribution changed. There was a significant decrease in number of younger patients in 2020, followed by a normalization of new cases in those 2-5 years old, which may have led to the belief that more toddlers were being diagnosed. The rate of other antibodies did not increase. These results illustrate that changes in demographics may have been short-lived post-COVID-19.

Abstract Image

Abstract Image

Abstract Image

新型冠状病毒肺炎时代1型糖尿病诊断年龄及人口统计学变化
自COVID-19发病以来,儿科内分泌学家一直在假设1型糖尿病(T1DM)的诊断年龄向更年幼的儿童转移。年龄较小的儿童更容易出现DKA,更难以诊断和治疗,并且诊断时的年龄会影响预后。我们对新冠肺炎前3年和新冠肺炎期间3年诊断为T1DM的患者进行了回顾性图表回顾。对分类数据使用卡方检验,对连续数据使用学生t检验或方差分析来评估人口统计学。在此期间,698名患者被诊断为T1DM,更多患者在COVID-19期间被诊断为T1DM。平均诊断年龄明显增加0.7岁(p=0.025)。两个时间段的年龄组分布差异有统计学意义(p=0.0065)。从2017年到2020年,2-5岁患者的新病例显著减少,这是一个短暂的发现,因为到2022年他们的发病率又回到了以前的水平。在2020年之前,13至18岁之间的新诊断增加(7%-23%),随后趋于平稳。患者在COVID-19期间出现DKA的可能性是其1.6倍;然而,血红蛋白A1c (HbA1c)没有明显变化。甲状腺过氧化物酶(TPO)抗体阳性无明显变化。组织转谷氨酰胺酶(TTG)-IgA升高的患者从感染前到感染后显著降低(p=0.018)。自COVID-19开始以来,我们的队列中诊断时的平均年龄有所增加,这与之前的研究和我们的假设相矛盾。新发病例数量增加,年龄分布发生变化。2020年,年轻患者的数量显著减少,随后2-5岁儿童的新病例正常化,这可能导致人们认为更多的幼儿被诊断出来。其他抗体的比例没有增加。这些结果表明,covid -19后人口结构的变化可能是短暂的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pediatric Diabetes
Pediatric Diabetes 医学-内分泌学与代谢
CiteScore
6.60
自引率
14.70%
发文量
141
审稿时长
4-8 weeks
期刊介绍: Pediatric Diabetes is a bi-monthly journal devoted to disseminating new knowledge relating to the epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes in childhood and adolescence. The aim of the journal is to become the leading vehicle for international dissemination of research and practice relating to diabetes in youth. Papers are considered for publication based on the rigor of scientific approach, novelty, and importance for understanding mechanisms involved in the epidemiology and etiology of this disease, especially its molecular, biochemical and physiological aspects. Work relating to the clinical presentation, course, management and outcome of diabetes, including its physical and emotional sequelae, is considered. In vitro studies using animal or human tissues, whole animal and clinical studies in humans are also considered. The journal reviews full-length papers, preliminary communications with important new information, clinical reports, and reviews of major topics. Invited editorials, commentaries, and perspectives are a regular feature. The editors, based in the USA, Europe, and Australasia, maintain regular communications to assure rapid turnaround time of submitted manuscripts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书